Clinical Trials Browser

Phase 1/2 × INDUSTRY × Newly Diagnosed Glioblastoma × Clear all

NCT04065087 2022-03-17

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Withdrawn

Newly Diagnosed Glioblastoma